Zanubrutinib is a medication used in this trial to treat certain types of lymphoma, which is a cancer of the lymphatic system. It works by blocking a specific protein in cancer cells, which helps to stop the cancer from growing and spreading. This medication is being tested in combination with other treatments to see if it can improve outcomes for patients with relapsed or refractory follicular or marginal zone lymphoma.

Obinutuzumab is an antibody therapy used in this trial. It targets a specific protein found on the surface of certain cancer cells. By attaching to this protein, obinutuzumab helps the immune system to recognize and destroy the cancer cells. It is being combined with zanubrutinib in the study to evaluate its effectiveness in treating lymphoma.

Lenalidomide is a medication that helps the immune system fight cancer. It works by affecting the way the immune system functions and can also stop cancer cells from growing. In this trial, lenalidomide is being used with another antibody therapy to see if it can help treat patients with relapsed or refractory lymphoma.

Rituximab is an antibody therapy that targets a specific protein on the surface of cancer cells. By binding to this protein, rituximab helps the immune system to attack and kill the cancer cells. It is being used in combination with other treatments in this study to assess its effectiveness in treating lymphoma.

Marginal Zone Lymphoma – Marginal zone lymphoma is a type of non-Hodgkin lymphoma that originates in the marginal zone of lymphoid tissue, which is part of the immune system. It typically progresses slowly and may initially present with symptoms such as swollen lymph nodes, fatigue, or weight loss. As the disease advances, it can spread to other parts of the body, including the spleen, bone marrow, or other organs. The progression of marginal zone lymphoma can vary, with some patients experiencing long periods of stability, while others may see a more rapid advancement of symptoms. The disease is often characterized by the accumulation of abnormal B-cells, which are a type of white blood cell. Over time, these abnormal cells can interfere with normal immune function.

Follicular Lymphoma – Follicular lymphoma is a common type of indolent non-Hodgkin lymphoma that arises from B-cells, a type of white blood cell. It typically progresses slowly and is often diagnosed at an advanced stage due to its subtle symptoms, such as painless swelling of lymph nodes, fatigue, or night sweats. The disease is characterized by the formation of tumor-like clusters of abnormal B-cells in lymph nodes, which can eventually spread to other lymphoid tissues and organs. As follicular lymphoma advances, it may transform into a more aggressive form of lymphoma, leading to a faster progression of symptoms. The course of the disease can vary significantly among individuals, with some experiencing long periods of remission. Despite its slow progression, follicular lymphoma requires careful monitoring to manage its impact on the body.